Biotech Values

[jb_118]

re: EDIT

I do wonder if there's any potential positive read-through to the other CRISPR players like CRSP or if this is potentially a negative broad read-through for the entire field (my gut is the latter).

My gut agrees with your gut, that it's the latter, at least with respect to the current iteration of CRISPR/Cas9 companies. Just to be clear, this is in respect to human in vivo genome editing. It works great in the lab and biological experimentation.